INWOOD LABS ESTABLISHING IN-PROCESSING CONTROLS FOR INDOMETHACIN
INWOOD LABS ESTABLISHING IN-PROCESSING CONTROLS FOR INDOMETHACIN manufacturing in response to FD-483 observations that resulted from a November-December 1993 inspection of the generic firm's Inwood, New York facility. Inwood is creating "in- processing limits, controls and specifications for production of indomethacin [75 mg] extended-release capsules" and using "new/additional manufacturing instructions," according to an April 22 warning letter to Inwood's parent firm, Forest Labs, discussing Forest's past communications with FDA.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth